Recent breakthroughs indicate that inhibition of hydrogen peroxide permeation through AQP1 provides a new approach to treat hypertrophic cardiomyopathies, and inhibition of AQP4 localization with the licensed drug trifluoperazine provides compelling evidence for a new approach to treating CNS edema (Salman et al., 2022). This evidence concerns the gene AQP4 and hypertrophic cardiomyopathy.